Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Corcept Therapeutics (CORT) Operating Margin (2016 - 2025)

Historic Operating Margin for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to 4.92%.

  • Corcept Therapeutics' Operating Margin fell 206100.0% to 4.92% in Q3 2025 from the same period last year, while for Sep 2025 it was 8.85%, marking a year-over-year decrease of 139600.0%. This contributed to the annual value of 20.29% for FY2024, which is 19500.0% down from last year.
  • Latest data reveals that Corcept Therapeutics reported Operating Margin of 4.92% as of Q3 2025, which was down 206100.0% from 13.72% recorded in Q2 2025.
  • In the past 5 years, Corcept Therapeutics' Operating Margin ranged from a high of 37.69% in Q3 2021 and a low of 2.17% during Q1 2025
  • Over the past 5 years, Corcept Therapeutics' median Operating Margin value was 24.72% (recorded in 2021), while the average stood at 22.97%.
  • Its Operating Margin has fluctuated over the past 5 years, first surged by 90600bps in 2021, then tumbled by -206100bps in 2025.
  • Quarter analysis of 5 years shows Corcept Therapeutics' Operating Margin stood at 37.1% in 2021, then tumbled by -41bps to 21.83% in 2022, then grew by 7bps to 23.39% in 2023, then tumbled by -41bps to 13.89% in 2024, then plummeted by -65bps to 4.92% in 2025.
  • Its Operating Margin was 4.92% in Q3 2025, compared to 13.72% in Q2 2025 and 2.17% in Q1 2025.